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InsBACKGROUND The relationship between the benefits of empagliflozin in heart failure with reduced ejection fraction
(HFrEF) and N-terminal pro–B-type natriuretic peptide (NT-proBNP) has not been reported.
OBJECTIVES The authors sought to evaluate the relationship between NT-proBNP and empagliflozin effects in
EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction).
METHODS Patients with HFrEF were randomly assigned to placebo or empagliflozin 10 mg daily. NT-proBNP was
measured at baseline, 4 weeks, 12 weeks, 52 weeks, and 100 weeks. Patients were divided into quartiles of
baseline NT-proBNP.
RESULTS Incidence rates for each study outcome were 4- to 6-fold higher among those in the highest versus lowest
NT-proBNP quartiles ($3,480 vs <1,115 pg/mL). Study participants with higher NT-proBNP had 2- to 3-fold total hos-
pitalizations higher than the lowest NT-proBNP quartile. Empagliflozin reduced risk for major cardiorenal events without
heterogeneity across NT-proBNP quartiles (primary endpoint Pinteraction ¼ 0.94; renal composite endpoint
Pinteraction ¼ 0.71). Empagliflozin treatment significantly reduced NT-proBNP at all timepoints examined; by 52 weeks, the
adjusted mean difference from placebo was 13% (P < 0.001). An NT-proBNP in the lowest quartile (<1,115 pg/mL)
12 weeks after randomization was associated with lower risk for subsequent cardiovascular death or heart failure hos-
pitalization regardless of baseline concentration. Treatment with empagliflozin resulted in 27% higher adjusted odds of
an NT-proBNP concentration of <1,115 pg/mL by 12 weeks compared with placebo (P ¼ 0.01).
CONCLUSIONS In EMPEROR-Reduced, higher baseline NT-proBNP concentrations were associated with greater risk for
adverse heart failure or renal outcomes, but empagliflozin reduced risk regardless of baseline NT-proBNP concentration.
The NT-proBNP concentration after treatment with empagliflozin better informs subsequent prognosis than pretreat-
ment concentrations. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction
[EMPEROR-Reduced]; NCT03057977) (J Am Coll Cardiol 2021;78:1321–1332) © 2021 The Authors. Published by Elsevier
on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2021.07.046
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ABBR EV I A T I ON S
AND ACRONYMS
CV = cardiovascular
eGFR = estimated glomerular
filtration rate
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
LVEF = left ventricular ejection
fraction
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1322A mong patients affected by heart fail-ure (HF) with reduced ejectionfraction (HFrEF), elevated concen-
trations of N-terminal pro–B-type natriuretic
peptide (NT-proBNP) are associated with
more severe symptoms, worse health status,
and a higher risk for hospitalization for HF
or cardiovascular (CV) death (1). Elevated or
rising concentrations of NT-proBNP in pa-
tients with HFrEF are associated with a more
decompensated hemodynamic profile, higher
filling pressures, and greater risk for progres-
sive adverse cardiac remodeling, hospitaliza-
tion, and death (1-4). In contrast, a reductionof NT-proBNP values following treatment for HFrEF
predicts an improved outcome, better health status,
and a higher likelihood for favorable reverse cardiac
remodeling (1,2,5). Most treatments that reduce mor-
tality or hospitalization in HFrEF produce some reduc-
tion in NT-proBNP concentrations (6).SEE PAGE 1333Sodium-glucose cotransporter-2 (SGLT2) inhibitors
have been added to the foundational treatments for
chronic HFrEF. When added to standard HF care,
both empagliflozin and dapagliflozin reduced rates of
hospitalization or CV death and improved health
status (7,8); recent data have also suggested that
empagliflozin may lead to reverse cardiac remodeling
in HF (9-12), which may, in turn, contribute to lower
NT-proBNP concentrations.
Although a reduction in the concentration of NT-
proBNP has been reported following treatment with
SGLT2 inhibitors among patients with type 2 diabetes
(most of whom did not have HFrEF) (13), the signifi-
cance of NT-proBNP measurement among patients
with chronic HFrEF treated with SGLT2 inhibitors is
not well understood. In this context, we explored
whether baseline NT-proBNP concentrations influ-
ence the efficacy of SGLT2 inhibitors in HFrEF, how
and over what timescale and pattern SGLT2 inhibitors
affect concentrations of NT-proBNP in HFrEF, and
how changes in NT-proBNP after empagliflozin
treatment are related to subsequent outcomes.on, MD, served as Guest Associate Editor for this paper. Christie
s attest they are in compliance with human studies committe
and Food and Drug Administration guidelines, including patien
thor Center.
received June 15, 2021; revised manuscript received July 12, 202METHODS
The Institutional Review Board of each study site
approved of all study procedures, and all patients
provided informed consent.
STUDY DESIGN. The design and primary results of
the EMPEROR-Reduced (Empagliflozin Outcome Trial
in Patients With Chronic Heart Failure With Reduced
Ejection Fraction; NCT03057977) trial have been
recently reported (8,14). In brief, the study included
HF patients with a left ventricular ejection fraction
(LVEF) of #40% and New York Heart Association
functional class II to IV and randomized them in a
double-blind manner to receive placebo or empagli-
flozin 10 mg daily. To prioritize the recruitment of
patients at higher risk, either a hospitalization within
12 months of study enrollment or an elevated NT-
proBNP concentration was required for study inclu-
sion. The NT-proBNP inclusion criteria were $600;
1,000; and 2,500 pg/mL in patients with an LVEF
of #30%, 31%-35%, and 36%-40%, respectively; these
thresholds were doubled in patients with
atrial fibrillation.
The primary endpoint of EMPEROR-Reduced was
the time to first event in a composite of CV death or
hospitalization for HF. Two secondary endpoints
were included into the study testing hierarchy: 1) the
occurrence of all (first and recurrent) hospitalizations
for HF; and 2) the slope of the change in estimated
glomerular filtration rate (eGFR) during double-blind
treatment. Major adverse renal outcomes were
assessed by the need for renal replacement therapy
or transplant or by the occurrence of sustained
severe reductions in eGFR of $40% or reduction
to <15 mL/min/1.73 m2 (if baseline eGFR was
$30 mL/min/1.73 m2) or eGFR of <10 mL/min/1.73 m2
(if baseline eGFR was <30 mL/min/1.73 m2). Changes
in the Kansas City Cardiomyopathy Questionnaire
Clinical Summary score across 52 weeks of follow-up
were also evaluated.
As part of the study design, blood was collected for
measurement of NT-proBNP (Roche Diagnostics) at
baseline and again at 4, 12, 52, and 100 weeks.Ballantyne, MD, served as Guest Editor-in-Chief for
es and animal welfare regulations of the authors’
t consent where appropriate. For more information,
1, accepted July 16, 2021.












(n [ 932) P Value
Age, y 64.4  11.0 66.6  10.7 67.6  11.0 68.8  11.0 <0.001
Female 211 (22.7) 230 (24.7) 225 (24.1) 227 (24.4) 0.76
Race 0.72
White 657 (70.6) 670 (71.9) 659 (70.6) 641 (68.8)
Black 70 (7.5) 60 (6.4) 58 (6.2) 69 (7.4)
Asian 161 (17.3) 152 (16.3) 181 (19.4) 178 (19.1)
Other or missing 42 (4.5) 50 (5.4) 36 (3.9) 44 (4.7)
Region 0.02
North America 114 (12.3) 116 (12.4) 94 (10.1) 101 (10.8)
Latin America 334 (35.9) 287 (30.8) 318 (34.0) 346 (37.1)
Europe 327 (35.2) 372 (39.9) 342 (36.6) 311 (33.4)
Asia 104 (11.2) 116 (12.4) 139 (14.9) 134 (14.4)
Other 51 (5.5) 41 (4.4) 41 (4.4) 40 (4.3)
Clinical course of heart failure
Duration of heart failure, y 3.4 (1.3-8.9) 4.3 (1.5-9.2) 4.2 (1.5-8.4) 4.1 (1.5-9.0) 0.37
NYHA functional class III-IV 163 (17.5) 209 (22.4) 231 (24.7) 326 (35.0) <0.001
Hospitalization for heart failure within 12 months 246 (26.5) 275 (29.5) 288 (30.8) 342 (36.7) <0.001
Left ventricular ejection fraction, % 27.6  5.5 27.4  6.0 27.7  6.1 27.1  6.5 0.16
KCCQ-CSS 75.2  20.3 72.0  20.8 70.1  22.3 65.6  23.2 <0.001
Body mass index, kg/m2 28.8  5.3 28.7  5.5 27.6  5.3 26.4  5.1 <0.001
Heart rate, beats/min 70.1  10.5 70.4  11.3 71.4  12.0 73.2  12.8 <0.001
Systolic blood pressure, mm Hg 123.0  15.2 122.3  15.3 121.9  15.8 120.8  16.2 0.03
Medical history
Ischemic cause of heart failure 516 (55.5) 496 (53.2) 457 (48.9) 459 (49.2) 0.01
History of myocardial infarction 426 (45.8) 423 (45.4) 388 (41.5) 385 (41.3) 0.08
History of coronary revascularization 391 (42.0) 389 (41.7) 373 (39.9) 369 (39.6) 0.62
Diabetes mellitus 460 (49.5) 458 (49.1) 462 (49.5) 474 (50.9) 0.88
History of atrial fibrillation or flutter 226 (24.3) 363 (38.9) 425 (45.5) 427 (45.8) <0.001
Atrial fibrillation at baseline 52 (5.6) 178 (19.1) 257 (27.5) 246 (26.4) <0.001
Hypertension 653 (70.2) 682 (73.2) 676 (72.4) 686 (73.6) 0.37
HF management, baseline
ACE inhibitor/ARB 661 (71.1) 645 (69.2) 672 (71.9) 621 (66.6) 0.06
ARNI 212 (22.8) 204 (21.9) 157 (16.8) 154 (16.5) <0.001
Beta blocker 890 (95.7) 885 (95.0) 877 (93.9) 880 (94.4) 0.34
Mineralocorticoid receptor antagonist 694 (74.6) 661 (70.9) 671 (71.8) 633 (67.9) 0.02
Loop diuretic 745 (80.1) 773 (82.9) 800 (85.7) 831 (89.2) <0.001
ICD (including CRT-D) 301 (32.4) 311 (33.4) 303 (32.4) 255 (27.4) 0.02
Laboratory findings
eGFR, mL/min/1.73 m2 69.8  21.3 63.8  21.0 59.8  20.3 54.6  21.1 <0.001
eGFR of <60 mL/min/1.73 m2 308 (33.1) 425 (45.6) 479 (51.3) 587 (63.0) <0.001
Uric acid, mg/dL 6.71  1.79 6.90  1.93 7.16  2.10 7.66  2.33 <0.001
Values are mean  SD, n (%), or median (interquartile range). P values compare group means using analysis of variance for continuous variables and the chi-square test for
categorical variables.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker; ARNI ¼ angiotensin receptor/neprilysin inhibitor; CRT-D ¼ cardiac resynchronization therapy–
defibrillator; eGFR ¼ estimated glomerular filtration rate; HF ¼ heart failure; ICD ¼ implantable cardioverter-defibrillator; KCCQ-CSS ¼ Kansas City Cardiomyopathy
Questionnaire Clinical Summary Score; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association.
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1323STATISTICAL ANALYSIS. Study participants were
categorized by NT-proBNP quartiles, and baseline
characteristics were compared.
Geometric mean concentrations of NT-proBNP were
analyzed across study visits using a mixed model with
repeated measures, adjusted for age, baseline eGFR,
region, baseline diagnosis of diabetes, sex, LVEF, lastprojected visit based on dates of randomization
and trial closure, baseline log-transformed NT-
proBNP, treatment-by-visit interaction, and baseline
log-transformed NT-proBNP–by–visit interaction.
Comparisons between treatment groups at various
timepoints were made using the adjusted geometric
mean ratio.





















Time to first event of CV death or hospitalization for HF
Time to first event of CV death
Time to first event of hospitalization for HF





Hazard Ratio (95% CI)
2 4
<1,115 pg/mL 4/488 (0.8) 11/442 (2.5) 0.34 (0.11-1.06)2.30.8
0.711,115-1,909 pg/mL 8/454 (1.8) 12/478 (2.5) 0.63 (0.26-1.54)2.41.6
1,910-3,479 pg/mL 5/459 (1.1) 13/475 (2.6) 0.44 (0.16-1.23)2.61.1
≥3,480 pg/mL 13/461 (2.8) 22/471 (4.7) 0.52 (0.26-1.03)5.33.0
All patients 1.630/1,863 (1.6) 58/1,867 (3.1) 0.50 (0.32-0.77)3.1
<1,115 pg/mL 24/488 (4.9) 34/442 (7.7) 0.64 (0.38-1.07)5.93.8
0.141,115-1,909 pg/mL 39/454 (8.6) 74/478 (15.5) 0.54 (0.36-0.79)12.36.5
1,910-3,479 pg/mL 59/459 (12.9) 88/475 (18.5) 0.69 (0.50-0.96)15.310.5
≥3,480 pg/mL 124/461 (26.9) 146/471 (31.0) 0.78 (0.62-1.00)32.625.3
All patients 10.8246/1,863 (13.2) 342/1,867 (18.3) 0.69 (0.59-0.81)15.6
<1,115 pg/mL 34/488 (7.0) 22/442 (5.0) 1.44 (0.84-2.47)3.65.2
0.181,115-1,909 pg/mL 32/454 (7.0) 37/478 (7.7) 0.89 (0.56-1.43)5.65.1
1,910-3,479 pg/mL 35/459 (7.6) 51/475 (10.7) 0.75 (0.49-1.16)7.85.8
≥3,480 pg/mL 86/461 (18.7) 91/471 (19.3) 0.89 (0.66-1.19)16.214.7
All patients 7.6187/1,863 (10.0) 202/1,867 (10.8) 0.92 (0.75-1.12)8.1
0.941,115-1,909 pg/mL 57/454 (12.6) 92/478 (19.2) 0.62 (0.45-0.87)15.39.5
<1,115 pg/mL 54/488 (11.1) 51/442 (11.5) 0.97 (0.66-1.42)8.98.5
1,910-3,479 pg/mL 80/459 (17.4) 122/475 (25.7) 0.67 (0.51-0.89)21.314.2
≥3,480 pg/mL 170/461 (36.9) 196/471 (41.6) 0.80 (0.65-0.98)43.734.7
All patients 15.8361/1,863 (19.4) 462/1,867 (24.7) 21.0 0.75 (0.65-0.86)
Outcomes and treatment effect are expressed as a function of NT-proBNP quartile. CV ¼ cardiovascular; EMPEROR-Reduced ¼ Empagliflozin Outcome Trial in Patients
With Chronic Heart Failure With Reduced Ejection Fraction; HF ¼ heart failure; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
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1324Time-to-event analyses were performed using Cox
proportional hazards models, adjusting for age, sex,
region, baseline diagnosis of diabetes, LVEF, and
eGFR at baseline. A joint frailty model was used for
the analysis of total (ie, first and potentially recur-
rent) events, incorporating the same variables as the
time-to-event analyses and including death as a
competing risk. Changes in eGFR slope were analyzed
using a random coefficient model using on-treatmentdata, with age and baseline eGFR as linear covariates
and sex, region, LVEF, diabetes status, baseline
eGFR-by-time, treatment–by–NT-proBNP (quartile),
and treatment–by–time–by–NT-proBNP (quartile)
interaction terms as fixed effects. Given the stratified
NT-proBNP inclusion criteria for those with an LVEF
of >30%, a sensitivity analysis that focused only on
those patients with an LVEF of #30% was also
performed.









per 100 Patient-Years HR (95% CI)
P Value
for Trend
Q1: <1,115 pg/mL 35 5.4 51 8.5 0.67 (0.41-1.11) 0.49
Q2: 1,115-1,909 pg/mL 57 9.1 118 18.0 0.52 (0.35-0.77)
Q3: 1,910-3,479 pg/mL 107 17.7 136 20.9 0.85 (0.60-1.22)
Q4: $3,480 pg/mL 189 32.5 248 44.5 0.71 (0.52-0.970)
Values are n unless otherwise indicated. Empagliflozin reduced heart failure hospitalization similarly across NT-proBNP quartiles.
NT-proBNP ¼ N-terminal pro-B type natriuretic peptide; Q ¼ quartile.
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1325In an effort to understand how the change in NT-
proBNP informs outcome, study participants in
pooled empagliflozin and placebo groups were cate-
gorized as “low” (if in the lowest quartile) or “high”
(if in quartiles 2-4) at both baseline and at 12 weeks
after randomization; this yielded 4 NT-proBNP cate-
gories (low/low, high/low, low/high, and high/high).
Time to the primary endpoint was evaluated across
these 4 groups by landmark analysis using Cox pro-
portional hazards modeling, as described, with the
landmarked data beginning at week 12, to assess the
association between NT-proBNP at 2 time points
and the differences in the risk of subsequent events
after 12 weeks. The 12-week visit was scheduled in a
visit window of 12 weeks  7 days, with values of
NT-proBNP mapped to the closest planned visit,
where used (if no other values were available), that
was closer to the planned measurement. This way,
NT-proBNP values were measured at as early as
8 weeks or as late as 16 weeks. Because the quartiles
of NT-proBNP were ordered, trend tests were used
for the calculation of P values to evaluate the influ-
ence of baseline values for NT-proBNP on CV and
renal outcomes, using the covariate adjustments as
described.
All analyses were performed using SAS, version 9.4
(SAS Institute). The P values reported are 2-sided,
with P < 0.05 considered statistically significant. No
adjustments for multiple testing were made.
DATA SHARING. Data will be made available on
request in adherence with transparency conventions
in medical research and through requests to the cor-
responding author. Following execution of pre-
specified analyses, a full database will be made
available in adherence with the transparency policy
of the sponsor.
RESULTS
Baseline NT-proBNP results were available in 3,728
study participants; the median NT-proBNP value atbaseline was 1,910 pg/mL (interquartile range: 1,115-
3,480 pg/mL).
NT-proBNP AND BASELINE CHARACTERISTICS.
Characteristics of the study participants by baseline
NT-proBNP quartiles are described in Table 1. Pa-
tients with higher NT-proBNP values were older and
had greater medical complexity, including more
atrial fibrillation, higher rates of recent hospitaliza-
tion, and poorer health status (P < 0.001 for all
comparisons). Consistent with the design of the
study (with higher inclusion NT-proBNP concentra-
tions for those with higher LVEF), no significant dif-
ference in the LVEF was found across quartiles.
Those with higher baseline NT-proBNP concentra-
tions were less likely to be treated with neurohor-
monal antagonists but were more likely to be treated
with loop diuretics.
BASELINE NT-proBNP AND STUDY OUTCOME. Across
NT-proBNP quartiles, there was a significant and
clinically meaningful increase in the rates of the pri-
mary endpoint of CV death/HF hospitalization and its
individual components. Among those randomized to
placebo in the highest NT-proBNP quartile, there was
>4-fold higher incidence rate/100 patient-years for
the CV death, HF hospitalization, or the combined
risk of both events. Treatment with empagliflozin
reduced events across NT-proBNP quartiles without
interaction with baseline NT-proBNP (P value for
trend >0.05) (Figure 1).
There was a stepwise increase in total HF hospi-
talizations with a doubling of total hospitalizations
across NT-proBNP among patients treated with pla-
cebo (Table 2). Empagliflozin reduced the risk of total
hospitalizations for HF by approximately 30% in the
lowest and highest NT-proBNP quartiles, with no
significant treatment–by–NT-proBNP heterogeneity
(P value for trend ¼ 0.49). Similar results were seen if
all-cause (rather than CV) mortality was used in the
joint frailty model (HR: 0.66, 0.52, 0.84, and 0.73
across quartiles, respectively).
TABLE 3 Mean Slope of Change in Estimated Glomerular Filtration Rate Relative to











Q1: <1,115 pg/mL –0.58 –1.65 1.07 (–0.16 to 2.30) 0.27
Q2: 1,115-1,909 pg/mL –0.58 –2.47 1.89 (0.67 to 3.12)
Q3: 1,910-3,479 pg/mL –0.02 –1.94 1.92 (0.67 to 3.17)
Q4: $3,480 pg/mL –1.14 –3.29 2.15 (0.79 to 3.51)
Empagliflozin reduced decline in kidney function regardless of NT-proBNP quartile.
Abbreviations as in Table 2.
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1326The rate of decline in eGFR was related to the
baseline NT-proBNP, with the largest decrease in
renal function noted among those with higher
NT-proBNP values (Table 3); specifically, the mean
slope of change among placebo patients in
NT-proBNP was 1.65 mL/min/1.73 m2/year in quar-
tile 1 and 3.29 mL/min/1.73 m2/year in quartile 4.
Empagliflozin slowed the rate of eGFR decline
in each quartile, with no significant treatment–
by–NT-proBNP heterogeneity (P value for trend
¼ 0.27). In addition, rates of the renal composite
endpoint were associated with baseline NT-proBNP,
with the largest decrease in renal function among
those with higher NT-proBNP concentrations (P <
0.001) (Figure 1); empagliflozin reduced rates of the
renal composite endpoint without treatment inter-
action with NT-proBNP. In a sensitivity analysis using
a shared random effects model with all-cause mor-
tality considered as a competing risk, the mean slope
of change of eGFR was greatest at higher NT-proBNP
concentrations (Supplemental Table 1).
Changes in the adjusted mean Kansas City Car-
diomyopathy Questionnaire Clinical Summary scores
were comparable across study visits and NT-proBNP
quartiles, with generally larger improvements seen
in those treated with empagliflozin (Supplemental
Figure 1).
CHANGE IN NT-proBNP OVER TIME AND EFFECT OF
EMPAGLIFLOZIN. NT-proBNP concentrations at
study visits in the 2 treatment groups are shown in
Figure 2 and Supplemental Table 2. At 4 weeks
following randomization, treatment with empagli-
flozin 10 mg lowered NT-proBNP concentrations (as
compared to placebo) (adjusted geometric mean ratio:
0.95; 95% CI: 0.92-0.99; P ¼ 0.009); this difference
persisted across all study timepoints, with the largest
difference being seen at 52 weeks (adjusted geometric
mean ratio: 0.87; 95% CI: 0.82-0.93; P < 0.001). A
histogram visualizing absolute NT-proBNP change
from baseline to 52 weeks is shown in Supplemental
Figure 2; those randomized to empagliflozin 10 mgwere more likely to show a reduction in NT-proBNP
concentrations by 52 weeks, whereas those random-
ized to placebo were more likely to show an increase
in NT-proBNP concentrations.
CHANGE IN NT-proBNP BY 12 WEEKS AND
OUTCOME. Change in NT-proBNP between baseline
and 12 weeks and subsequent outcome was evaluated
in a landmark analysis of study participants free of
primary endpoint events starting at 12 weeks after
randomization; 87% of 3,730 randomized patients
were included in the analysis. Patients in pooled
empagliflozin and placebo groups were categorized
according to their absolute values of NT-proBNP at
these 2 timepoints; that is, they were grouped as
“low” (quartile 1: <1,115 pg/mL) or “high” (quartiles
2-4: $1,115 pg/mL), thus yielding 4 groups: “low/
low,” “high/low,” “low/high,” and “high/high.”
Using data landmarked beginning at week 12,
Kaplan-Meier plots show that the risk for the primary
endpoint of CV death/HF hospitalization was lower
for those with NT-proBNP values of <1,115 pg/mL at
this timepoint when compared to those in higher
quartiles (Supplemental Figure 3). When patients
were categorized by their baseline and 12-week
NT-proBNP, we found that patients were at lower
risk if they had an NT-proBNP of <1,115 pg/mL,
regardless of the baseline value of NT-proBNP
(Figure 3). When compared to the referent category
of “high/high,” those with an NT-proBNP of <1,115
pg/mL by 12 weeks had a lower adjusted hazard for CV
death/HF hospitalization, regardless of their baseline
value for NT-proBNP (“low/low” HR: 0.35; 95% CI:
0.26-0.46; P < 0.001; “high/low” HR: 0.23; 95% CI:
0.15-0.35; P < 0.001). Notably, in those who started
“low” but by 12 weeks had an NT-proBNP of $1,115 pg/
mL, the HR was 0.61 (95% CI: 0.41-0.91; P ¼ 0.01)
(Figure 4).
The number and proportion of patients in each
category are shown in Supplemental Table 3, which
shows the effect of empagliflozin in lowering
NT-proBNP concentrations at 12 weeks. In a model
adjusted for age, sex, LVEF, region, diabetes, baseline
eGFR, and baseline NT-proBNP as compared with
placebo, treatment with empagliflozin resulted in a
27% (95% CI: 5.6-52.6) higher likelihood of having an
NT-proBNP of <1,115 pg/mL (P ¼ 0.01). Furthermore,
among those with an NT-proBNP of $1,115 pg/mL at
baseline, across the entire time of the study, treat-
ment with empagliflozin resulted in an adjusted 35%
(95% CI: 17-56) higher likelihood of achieving an
NT-proBNP of <1,115 pg/mL compared with the
placebo group (P < 0.001).
SENSITIVITY ANALYSIS. No significant relative dif-
ference in NT-proBNP reduction after study entry was

















Week 4: 5% (1% to 8%)
P = 0.009
Week 12: 6% (2% to 10%)
P = 0.006
Week 52: 13% (7% to 18%)











































Empagliflozin 10 mg (n = 1,863)Placebo (n = 1,867)
Treatment with empagliflozin resulted in a significant reduction of NT-proBNP compared to placebo as early as 4 weeks and lasting across study visits.
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
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Table 4). Reduction of NT-proBNP as a function of
treatment assignment across LVEF categories is
shown in Supplemental Table 5. Finally, when eval-
uating only those patients with an LVEF of <30% at
inclusion, the outcome results for the primary
endpoint and effect of empagliflozin were similar
across NT-proBNP categories (Supplemental Table 6).
DISCUSSION
In this planned analysis of NT-proBNP concentrations
measured from HFrEF patients in the recent
EMPEROR-Reduced study, we have made 3 key ob-
servations (Central Illustration). First, in those
with higher baseline NT-proBNP, there was a more
severe clinical presentation and higher risk for
study endpoints, but the effect of empagliflozin onreducing the risk of adverse CV and renal outcomes
was similar across NT-proBNP quartiles. Second,
compared to placebo, empagliflozin resulted in
greater reductions of NT-proBNP concentrations; this
finding was observed early in the study and persisted
until the end of follow-up. Third, an NT-proBNP
of <1,115 pg/mL by 12 weeks in the study (a finding
more frequently present in those treated with empa-
gliflozin) was associated with lower subsequent risks.
These results add considerable information to the
understanding regarding the role and pattern of
NT-proBNP measurements in HFrEF patients treated
with SGLT2 inhibitors.
Through its design, the EMPEROR-Reduced trial
intended enrollment of higher-risk patients
with HFrEF. Reflecting this, the average NT-proBNP
concentration at baseline in this study was 1,910
pg/mL, one of the higher concentrations among


































































Follow-Up Days After 12 Weeks
40
Cumulative incidence of cardiovascular death or heart failure hospitalization is landmarked beginning at 12 weeks. Patients were categorized as “low” if they had an NT-
proBNP of <1,115 pg/mL at baseline or the 12-week mark; if they were above this cutoff, they were categorized as “high.” Regardless of starting concentration, if a
patient demonstrated an NT-proBNP of <1,115 pg/mL at 12 weeks, the prognosis was substantially better. NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
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1328recent trials of ambulatory HFrEF patients (15-17)
and, to our knowledge, the highest among ambula-
tory SGLT2 inhibitor trials reported thus far. In
EMPEROR-Reduced, higher baseline concentrations
of NT-proBNP were associated with more advanced
age and a more decompensated HF profile charac-
terized by worse New York Heart Association func-
tional class, greater burden of recent HF
hospitalization, poorest health status, and more
prevalent atrial arrhythmia or kidney dysfunction.
In keeping with this clinical profile, patients in the
highest NT-proBNP quartile were also least likely to
receive renin-angiotensin-aldosterone inhibitors and
most likely to be treated with loop diuretics.
A stepwise relationship was observed between the
baseline value of NT-proBNP and the risk for the
primary endpoint in placebo recipients. When
compared to those in the lowest NT-proBNP quartile
(<1,115 pg/mL), those in the highest NT-proBNP
quartile ($3,480 pg/mL) had a 4- to 6-fold excess
rate of CV death, HF hospitalization, or the composite
of both endpoints; they also had more than twice
the total number of HF hospitalizations. HigherNT-proBNP concentrations were also associated with
worse decline in renal function and higher rates of the
composite renal endpoint. Treatment with empagli-
flozin reduced the risk for each adverse outcome
across NT-proBNP quartiles without statistical het-
erogeneity. The large size of the EMPEROR-Reduced
trial allows for a comprehensive assessment of treat-
ment modification by baseline NT-proBNP and
suggests a consistent relative effect of SGLT2 inhibi-
tion to reduce key CV and renal endpoints across
NT-proBNP concentrations. Importantly, these re-
sults also demonstrate a consistent benefit of empa-
gliflozin in those with the highest NT-proBNP
concentrations, an important finding in light of recent
data suggesting the attenuation of the benefit of
vericiguat in patients with the highest NT-proBNP
values before treatment (18).
SGLT2 inhibitors may reduce concentrations of
NT-proBNP in patients with type 2 diabetes (13,19),
but recent smaller trials have returned conflicting
results as to the effect of SGLT2 inhibitors on natri-
uretic peptides in HF (20,21), where considerably
higher concentrations of these biomarkers are















Hazard Ratio (95% CI)
1 2
<0.00155/664 8.3 7.49 0.35 (0.26-0.46)Low/Low
0.0127/190 14.2 13.04 0.61 (0.41-0.91)Low/High
<0.00124/442 5.4 4.95 0.23 (0.15-0.35)High/Low
Reference438/1,937 22.6 22.00 ReferenceHigh/High
Study participants with NT-proBNP concentrations of <1,115 pg/mL by 12 weeks had lower risk for the primary endpoint of the EMPEROR-Reduced (Empagliflozin
Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction) trial, regardless of starting NT-proBNP concentration. NT-proBNP ¼ N-terminal
pro–B-type natriuretic peptide.
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1329expected. Thus, an important finding in this analysis
was evidence for a treatment effect of empagliflozin
to reduce NT-proBNP in HFrEF. A difference in
biomarker values was already significant by 4 weeks
after randomization, which became increasingly
apparent over time. By 52 weeks, empagliflozin
treatment resulted in an average 13% difference of
adjusted NT-proBNP concentrations compared to
placebo.
Serial measurement of NT-proBNP is frequently
used for risk monitoring in chronic HFrEF; therefore,
our results are clinically meaningful. We found
that those receiving empagliflozin were 27% more
likely than placebo-treated patients to have an
NT-proBNP below 1,115 pg/mL by 12 weeks. Prior
studies have identified an NT-proBNP concentration
of <1,000 pg/mL after HF treatment to be predictive
of substantially reduced risk in HFrEF compared to
higher achieved values and to be the point at which
the magnitude and speed of reverse cardiac remod-
eling are more pronounced (1,5), so this finding is
noteworthy. Of similar importance is the finding that
prognosis for CV death/HF hospitalization is better
informed by the 12-week NT-proBNP, regardless of
the baseline concentration. Similar data focused on
treatment with sacubitril/valsartan suggested that a
reduction of NT-proBNP to <1,000 pg/mL by 30 days
was also predictive of lower risk for CV death/HF
hospitalization regardless of baseline values (22), but
to our knowledge, these data are the first to show
an association between early change in NT-proBNP
and improved outcomes after treatment with an
SGLT2 inhibitor. We further extend the understand-
ing of how empagliflozin influences NT-proBNPconcentrations by showing that through the entire
course of the study among those with an NT-proBNP
of $1,115 pg/mL at baseline, treatment with empa-
gliflozin led to a 35% higher likelihood for an
NT-proBNP of <1,115 pg/mL compared with placebo.
Mechanistically, early and sustained longitudinal
reduction in NT-proBNP following treatment for
HFrEF may inform reverse cardiac remodeling after
treatment for HFrEF (3,5). Empagliflozin has recently
been shown to produce reverse remodeling in ran-
domized trials (9,12), but whether reduction in NT-
proBNP owing to treatment with an SGLT2 inhibitor
is associated with reverse cardiac remodeling cannot
be answered by this analysis. Nonetheless, these re-
sults may be of use for clinicians serially measuring
NT-proBNP concentrations for risk monitoring and
remodeling status.
Our data add to the evidence that treatments
reducing risk in HFrEF tend to durably reduce con-
centrations of NT-proBNP in parallel with reduced
risk for CV events and increase the likelihood for
reverse cardiac remodeling. Although more modest
than the effects of sacubitril/valsartan in reducing
NT-proBNP (23), the reduction of NT-proBNP due to
treatment with empagliflozin in this study is compa-
rable to that seen with several other drug therapies
for HFrEF (24-27). Such early and sustained reduction
in NT-proBNP may have implications for risk reduc-
tion related to treatment with empagliflozin. To fully
contextualize how change in NT-proBNP reflects the
benefit of empagliflozin in this trial, a full mediation
analysis relating change in all variables affected by
SGLT2 inhibition to the primary endpoint would be
necessary. This was previously done in a trial of
CENTRAL ILLUSTRATION Key Findings of the EMPEROR-Reduced NT-proBNP Analysis
Januzzi, Jr., J.L. et al. J Am Coll Cardiol. 2021;78(13):1321–1332.
Treatment with empagliflozin reduced cardiac and renal events equally, regardless of baseline NT-proBNP; however, empagliflozin reduced NT-proBNP
concentrations compared to placebo, and early NT-proBNP after empagliflozin treatment was associated with a greater reduction in events. EMPEROR-
Reduced ¼ Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction trial; NT-proBNP ¼ N-terminal pro–B-type
natriuretic peptide.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: In EMPEROR-Reduced, empagliflozin exerted benefits
on cardiorenal outcomes irrespective of baseline NT-proBNP
levels. Moreover, empagliflozin treatment resulted in reductions
in NT-proBNP, which was associated with improved outcomes.
TRANSLATIONAL OUTLOOK: Further studies generating
mechanistic insights on the benefits of empagliflozin treatment
in heart failure, in addition to the association with natriuretic
peptides, are warranted.
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where reduction of NT-proBNP accounted for a small
percentage of the mediation of HF reduction. Indeed,
although we report that empagliflozin resulted in a
reduction of NT-proBNP that predicted a posttreat-
ment reduction in risk, in this (as in other studies),
the magnitude of early benefit from SGLT2 inhibition
in HFrEF appears larger than the modest early
reduction in NT-proBNP related to treatment. Mech-
anistic data are needed to better elucidate how
NT-proBNP change reflects a benefit from SGLT2 in-
hibitors in HFrEF and how other biomarkers might
add meaningful information regarding the mediation
of reduced risk related to treatment with these
agents. A full mediation analysis, considering all
variables affected by empagliflozin in EMPEROR-
Reduced, is planned to address this complex issue.
STUDY LIMITATIONS. The results from this analysis
should be considered in the context of its strengths
and limitations. This analysis provides the first large-
scale data of serial NT-proBNP measurement among
patients with HFrEF treated with empagliflozin.
To our knowledge, these data represent the first
report of the longer-term effects of empagliflozin on
NT-proBNP concentrations and potential prognostic
ramifications of such changes. However, the mecha-
nism of the lowering of NT-proBNP by empagliflozin
cannot be answered by this data set. An important
feature of the EMPEROR-Reduced trial was an inclu-
sion criterion requirement of a higher NT-proBNP for
those with an LVEF closer to 40%, whereas those with
an LVEF of #30% could be enrolled regardless of their
NT-proBNP. Given the potential for a reduced treat-
ment effect among those with higher NT-proBNP
concentrations, this design might have biased the
result of the trial toward the null, but the results of
this analysis indicate otherwise. It is also noteworthy
that results for the primary endpoint relative to
NT-proBNP value were similar whether patients had
an LVEF of #30% or >30%.
CONCLUSIONS
Among patients in the EMPEROR-Reduced Trial,
treatment with empagliflozin reduced risk for CV and
renal endpoints similarly across NT-proBNP concen-
trations, including among the patients at highest risk
with most elevated baseline NT-proBNP concentra-
tions. Treatment with empagliflozin lowered NT-
proBNP concentrations, and the achievement of a
low-risk NT-proBNP concentration by 12 weeks was
more predictive of study endpoints than the baseline
NT-proBNP.FUNDING SUPPORT AND AUTHOR DISCLOSURES
The EMPEROR-Reduced trial was supported by Boehringer Ingelheim
and Eli Lilly and Company. Dr Januzzi is supported in part by the
Hutter Family Professorship at Harvard Medical School; is a Trustee
of the American College of Cardiology; is a board member of Imbria
Pharmaceuticals; has received grant support from Applied Thera-
peutics, Innolife, Novartis Pharmaceuticals, and Abbott Diagnostics;
has received consulting income from Abbott, Janssen, Novartis, and
Roche Diagnostics; and participates in Clinical Endpoint Committees/
Data Safety Monitoring Boards for Abbott, AbbVie, Amgen, Bayer,
CVRx, Janssen, MyoKardia, and Takeda. Dr Zannad has recently
received Steering Committee or Advisory Board fees from Amgen,
AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cardior,
CVRx, Janssen, LivaNova, Merck, Mundipharma, Novartis, Novo
Nordisk, and Vifor Fresenius. Dr Anker has received fees from Abbott,
Bayer, Boehringer Ingelheim, Cardiac Dimension, Cordio, Impulse
Dynamics, Novartis, Occlutech, Servier, and Vifor Pharma; and has
received grant support from Abbott and Vifor Pharma. Dr Butler is a
consultant for Abbott, Adrenomed, Amgen, Array, AstraZeneca,
Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Phar-
maceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luit-
pold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche,
V-Wave Limited, and Vifor. Dr Filippatos has lectured for and/or has
Committee Member contributions in trials sponsored by Medtronic,
Vifor, Servier, Novartis, Bayer, Amgen, and Boehringer Ingelheim. Dr
Pocock is a consultant for Boehringer Ingelheim. Dr Ferreira is a
consultant for Boehringer Ingelheim. Dr Sattar has consulted for
Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp
and Dohme, Novo Nordisk, Novartis, Sanofi, and Pfizer; and has
received grant support from Boehringer Ingelheim. Drs Vedin and
Schnee, Mr Cotton, and Ms Iwata are employees of Boehringer
Ingelheim Pharmaceuticals. Dr Packer has received personal fees
from Boehringer Ingelheim during the conduct of the study; and has
received personal fees from AbbVie, Akcea, Amarin, AstraZeneca,
Amgen, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson,
Lilly, Novartis, ParatusRx, Pfizer, Relypsa, Sanofi, Synthetic Biologics,
and Theravance outside the submitted work. All other authors have
reported that they have no relationships relevant to the contents of
this paper to disclose.
ADDRESS FOR CORRESPONDENCE: Dr James L.
Januzzi, Jr, Massachusetts General Hospital, 32 Fruit
Street, Yawkey 5984, Boston, Massachusetts 02114, USA.
E-mail: jjanuzzi@partners.org. Twitter: @JJHeart_doc.
Januzzi, Jr. et al J A C C V O L . 7 8 , N O . 1 3 , 2 0 2 1
NT-proBNP in EMPEROR-Reduced S E P T E M B E R 2 8 , 2 0 2 1 : 1 3 2 1 – 1 3 3 2
1332RE F E RENCE S1. Januzzi JL, Jr. Ahmad T, Mulder H, et al. Natri-
uretic peptide response and outcomes in chronic
heart failure with reduced ejection fraction. J Am
Coll Cardiol. 2019;74:1205–1217.
2. Januzzi JL, Jr. Camacho A, Pina IL, et al. Reverse
cardiac remodeling and outcome after initiation of
sacubitril/valsartan. Circ Heart Fail. 2020;13:
e006946.
3. Januzzi JL, Jr. Prescott MF, Butler J, et al. As-
sociation of change in N-terminal pro-B-type
natriuretic peptide following initiation of
sacubitril-valsartan treatment with cardiac struc-
ture and function in patients with heart failure
with reduced ejection fraction. JAMA.
2019;322(11):1085–1095.
4. Pina IL, Camacho A, Ibrahim NE, et al.
Improvement of health status following initiation
of sacubitril/valsartan in heart failure and reduced
ejection fraction. J Am Coll Cardiol HF. 2021;9:42–
51.
5. Daubert MA, Adams K, Yow E, et al. NT-proBNP
goal achievement is associated with significant
reverse remodeling and improved clinical out-
comes in HFrEF. J Am Coll Cardiol HF. 2019;7:158–
168.
6. Ferreira JP, Duarte K, Graves TL, et al. Natri-
uretic peptides, 6-min walk test, and quality-of-
life questionnaires as clinically meaningful
endpoints in HF trials. J Am Coll Cardiol. 2016;68:
2690–2707.
7. McMurray JJV, Solomon SD, Inzucchi SE, et al.
Dapagliflozin in patients with heart failure and
reduced ejection fraction. N Engl J Med. 2019;381:
1995–2008.
8. Packer M, Anker SD, Butler J, et al. Cardiovas-
cular and renal outcomes with empagliflozin in
heart failure. N Engl J Med. 2020;383:1413–1424.
9. Lee MMY, Brooksbank KJM, Wetherall K, et al.
Effect of empagliflozin on left ventricular volumes
in patients with type 2 diabetes, or prediabetes,
and heart failure with reduced ejection fraction
(SUGAR-DM-HF). Circulation. 2021;143:516–525.
10. Santos-Gallego CG, Requena-Ibanez JA, San
Antonio R, et al. Empagliflozin ameliorates dia-
stolic dysfunction and left ventricular fibrosis/
stiffness in nondiabetic heart failure: amultimodality study. J Am Coll Cardiol Img.
2021;14:393–407.
11. Santos-Gallego CG, Requena-Ibanez JA, San
Antonio R, et al. Empagliflozin ameliorates
adverse left ventricular remodeling in nondiabetic
heart failure by enhancing myocardial energetics.
J Am Coll Cardiol. 2019;73:1931–1944.
12. Santos-Gallego CG, Vargas-Delgado AP,
Requena-Ibanez JA, et al. Randomized trial of
empagliflozin in nondiabetic patients with heart
failure and reduced ejection fraction. J Am Coll
Cardiol. 2021;77:243–255.
13. Januzzi JL, Jr. Xu J, Li J, et al. Effects of can-
agliflozin on amino-terminal pro-B-type natri-
uretic peptide: implications for cardiovascular risk
reduction. J Am Coll Cardiol. 2020;76:2076–2085.
14. Packer M, Butler J, Filippatos GS, et al. Eval-
uation of the effect of sodium-glucose co-trans-
porter 2 inhibition with empagliflozin on morbidity
and mortality of patients with chronic heart failure
and a reduced ejection fraction: rationale for and
design of the EMPEROR-Reduced trial. Eur J Heart
Fail. 2019;21:1270–1278.
15. Armstrong PW, Pieske B, Anstrom KJ, et al.
Vericiguat in patients with heart failure and
reduced ejection fraction. N Engl J Med.
2020;382:1883–1893.
16. McMurray JJ, Packer M, Solomon SD. Nepri-
lysin inhibition for heart failure. N Engl J Med.
2014;371:2336–2337.
17. Teerlink JR, Diaz R, Felker GM, et al. Ome-
camtiv mecarbil in chronic heart failure with
reduced ejection fraction: GALACTIC-HF baseline
characteristics and comparison with contemporary
clinical trials. Eur J Heart Fail. 2020;22:2160–2171.
18. Ezekowitz JA, O’Connor CM, Troughton RW,
et al. N-terminal pro-B-Type natriuretic peptide
and clinical outcomes: Vericiguat Heart Failure
With Reduced Ejection Fraction Study. J Am Coll
Cardiol HF. 2020;8:931–939.
19. Januzzi Jr JL, Butler J, Jarolim P, et al. Effects
of canagliflozin on cardiovascular biomarkers in
older adults with type 2 diabetes. J Am Coll Car-
diol. 2017;70:704–712.
20. Nassif ME, Windsor SL, Tang F, et al. dapa-
gliflozin effects on biomarkers, symptoms, andfunctional status in patients with heart failure with
reduced ejection fraction: the DEFINE-HF trial.
Circulation. 2019;140:1463–1476.
21. Tanaka A, Hisauchi I, Taguchi I, et al. Effects of
canagliflozin in patients with type 2 diabetes and
chronic heart failure: a randomized trial (CANDLE).
ESC Heart Fail. 2020;7:1585–1594.
22. Zile MR, Claggett BL, Prescott MF, et al.
Prognostic implications of changes in N-terminal
pro-B-type natriuretic peptide in patients with
heart failure. J Am Coll Cardiol. 2016;68:2425–
2436.
23. Myhre PL, Vaduganathan M, Claggett B, et al.
B-type natriuretic peptide during treatment with
sacubitril/valsartan: the PARADIGM-HF trial. J Am
Coll Cardiol. 2019;73:1264–1272.
24. Anand IS, Fisher LD, Chiang YT, et al. Changes
in brain natriuretic peptide and norepinephrine
over time and mortality and morbidity in the Val-
sartan Heart Failure Trial (Val-HeFT). Circulation.
2003;107:1278–1283.
25. Olsson LG, Swedberg K, Cleland JG, et al.
Prognostic importance of plasma NT-pro BNP in
chronic heart failure in patients treated with a
beta-blocker: results from the Carvedilol or
Metoprolol European Trial (COMET) trial. Eur J
Heart Fail. 2007;9:795–801.
26. Rosenberg J, Gustafsson F, Remme WJ,
Riegger GA, Hildebrandt PR. Effect of beta-
blockade and ACE inhibition on B-type natriuretic
peptides in stable patients with systolic heart
failure. Cardiovasc Drugs Ther. 2008;22:305–311.
27. Udelson JE, Feldman AM, Greenberg B, et al.
Randomized, double-blind, multicenter, placebo-
controlled study evaluating the effect of
aldosterone antagonism with eplerenone on
ventricular remodeling in patients with mild-to-
moderate heart failure and left ventricular sys-
tolic dysfunction. Circ Heart Fail. 2010;3:347–353.
KEY WORDS heart failure, NT-proBNP,
prognosis
APPENDIX For supplemental tables and
figures, please see the online version of this
paper.
